Hot Keywords
Biomarker Discovery Autophagy and Cancer Breast Cancer Metastasis Brain Metastases Gastric Cancer Metastasis Lung Cancer Genetic Heterogeneity Colorectal Cancer Prostate Cancer Cancer Immunotherapy Circulating Tumor Cells Neuroendocrine Tumors

Top
Topic: Research Progress on KRAS Mutation in Cancer Metastasis and Treatment

A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 28 Feb 2021

Guest Editor(s)

  • Dr. Lucio Crinò
    Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.

    Website | E-mail

  • Dr. Angelo Delmonte
    Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.

    Website | E-mail

Special Issue Introduction

KRAS represents an oncogene of the RAS family. When mutated, KRAS acts as a driver oncogene in a number of different cancers; in particular it constitutes the most common mutation in lung adenocarcinoma (25%-30%), in colorectal cancer (30%-40%) and in pancreatic cancer (approximately 90%), being present also in bladder, head and neck cancers and in melanoma. Furthermore the variants encoded by KRAS gene are considered ubiquitous and expressed in different cancer cell lines and in tumor microenvironment. Mutant KRAS proteins activate downstream signalling, through the MAPK and PI3K signalling cascade and induce continuous, unregulated cell proliferation and cell immortalization by evading apoptosis.

Because of their widespread expression in human cancers and their critical role in cancer cell proliferation, mutant KRAS protein represents an ideal and crucial target for the molecular treatment strategies in cancer precision medicine. Today after years of unsuccessful trials, a number of KRAS specific inhibitors are tested in RAS-driven tumors and preliminary results in lung cancer appear very promising to open the way to develop an efficacious strategy for treating KRAS-driven tumors.

The current special issue will highlight the recent key findings in the field of KRAS-mutant cancers and new strategies to improve the therapy for these diseases.

Submission Deadline

28 Feb 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/JCMT/?IssueId=491
Submission Deadline: 28 Feb 2021
Contacts: Gladys Di, Assistant Editor, gladys@jcmtjournal.com

Published Articles

This special issue is now open for submission.
Copyright © 2021 OAE Publishing Inc. All Rights Reserved.